Form 4: BioLargo Director Linda Park Receives Equity Compensation Through Option Grant

BioLargo, Inc. Director Linda Park was granted options to purchase 93,750 shares of common stock at an exercise price of $0.20 per share as compensation for board services.

Summary

• Linda Park, a Director of BioLargo, Inc. (BLGO), acquired an option to purchase 93,750 shares of common stock.
• The option has an exercise price of $0.20 per share.
• The option becomes exercisable on June 30, 2025, and expires on June 30, 2035.
• This option was issued as payment for $18,750 in fees for board services rendered during the most recently completed quarterly period.
• The grant was made pursuant to BioLargo's 2024 Equity Incentive Plan.
• Following this transaction, Linda Park beneficially owns 1,053,731 derivative securities.

Sentiment

Score: 6

Explanation: The filing indicates standard corporate governance and compensation practices, which is a neutral to slightly positive signal as it shows alignment of director interests with shareholders. No significant negative or highly positive news is present.

Positives

• Issuance of equity compensation aligns director incentives with shareholder interests.
• The compensation is part of a formal 2024 Equity Incentive Plan, indicating structured governance.

Risks

• Dilution risk for existing shareholders if options are exercised, increasing the number of outstanding shares.
• Potential for future stock price volatility impacting the value of the options.

Future Outlook

No specific forward-looking statements or guidance are provided beyond the option's expiration date.

Industry Context

Equity compensation for directors is a common practice across industries, particularly in smaller or growth-oriented companies, to conserve cash and align interests. This filing reflects standard corporate governance practices for compensating board members.

Comparison to Industry Standards

• Granting stock options as compensation for board services is a common practice, aligning director incentives with long-term shareholder value, similar to practices at companies like XYZ Biotech or ABC Tech.
• The exercise price of $0.20 per share is specific to BioLargo's current valuation and compensation structure, and its competitiveness would depend on a broader analysis of peer compensation packages and company performance.

Corporate Governance

Related Party Transactions

• Issuance of options to Director Linda Park for board services, valued at $18,750, under the 2024 Equity Incentive Plan.

Stakeholder Impact

• Shareholders: Potential for minor dilution if options are exercised, but also improved alignment of director incentives with shareholder value.
• Employees: No direct impact mentioned.
• Customers: No direct impact mentioned.
• Suppliers: No direct impact mentioned.
• Creditors: Potential for slight reduction in cash outflow for director compensation, but overall minimal direct impact.

Next Steps

• Linda Park may exercise the options at any time after June 30, 2025, until June 30, 2035.
• Future Form 4 filings will be required for any subsequent transactions by Linda Park.

Key Dates

Recommendation

Keywords

BioLargo, BLGO, Linda Park, Director, SEC Form 4, Stock Option, Equity Compensation, Insider Transaction, Corporate Governance, 2024 Equity Incentive Plan